HighGravityDataBioMarin Pharmaceutical — Feb 19, 2025 release
Fiscal 2024 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001048477-25-000004
Showing in the filing
Weighted-Average Diluted Shares Outstanding (EPS assumption)
“approximately 200 million”
Period
FY2025
Measure
GAAP-tied
Source
Guidance table
All guidance in this release · 14
Revenue and profitability growth for FY2025
“Double-Digit”
VOXZOGO country availability for FY2027
“more than 60 countries”
VOXZOGO Revenue CAGR for FY2023
“exceeding 25%”
Enzyme Therapies long-term growth outlook (C… for the long term
“high single-digit CAGR”
Cost transformation program size for FY2024
“$500 million”
Non-GAAP Operating Margin for FY2026
“40%”
Total Revenues for FY2027
“approximately $4 billion”
Non-GAAP Operating Margin growth for FY2025
“14% (3.9 percentage points) Y/Y at the mid-point of guidance”
Operating cash flows for FY2027
“more than $1.25 billion”
Total Revenues for FY2025
“$3,100 to $3,200”
Non-GAAP Operating Margin % for FY2025
“32% to 33%”
Non-GAAP Diluted EPS for FY2025
“$4.20 to $4.40”
VOXZOGO contribution to full-year 2025 Total… for FY2025
“$900 million to $950 million”
Weighted-Average Diluted Shares Outstanding … for FY2025
“approximately 200 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
2025 Full-Year Financial Guidance (in millions, except % and EPS amounts) Item 2025 Guidance Total Revenues (1) $3,100 to $3,200 Non-GAAP Operating Margin % (2) 32% to 33% Non-GAAP Diluted EPS (2)(3) $4.20 to $4.40 (1) VOXZOGO contribution to full-year 2025 Total Revenues expected to be in the range of $900 million to $950 million. (2) Refer to Non-GAAP Information beginning on page 10 of this press release for definitions of Non-GAAP Operating Margin and Non-GAAP Diluted EPS. (3) Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding. BioMarin will host a conference call and webcast to discuss fourth quarter and full-year 2024 financial results today, Wednesday, February 19, 2025, at 4:30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at www.biomarin.com. U.S./Canada Dial-in Number: 800-715-9871 Replay Dial-in Number: 800-770-2030 International Dial-in Number: 646-307-1963 Replay International Dial-in Number: 609-800-9909 Conference ID: 1878833 Conference ID: 1878833 About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult to treat genetic conditions. To learn more, please visit www.biomarin.com. 5 Forward-Looking S
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.